Lexaria Bioscience Corp.

LEXX

US52886N4060

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
2.25 ^USD	-3.85%		-10.36%	+80.00%

Apr. 16	Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study	MT
Apr. 16	Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study	CI

LEXARIA BIOSCIENCE CORP. : Regulation FD Disclosure (form 8-K)

June 16, 2021 at 03:02 pm EDT

Item 7.01 Regulation FD Disclosure

On June 15, 2021, Lexaria Bioscience Corp. announced the positive results regarding its tolerability and pharmacokinetic animal study, VIRAL-A20-2 (the "Study") which evaluated DehydraTECH-enabled remdesivir and ebastine. The Study identified levels of remdesivir and ebastine in the bloodstream of male Sprague-Dawley rats at rates of two to three times higher with DehydraTECH than without, thus providing potential opportunities for the treatment of viral infections via oral drug delivery rather than injections.

Latest news about Lexaria Bioscience Corp.

Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study	Apr. 16	MT
Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study	Apr. 16	CI
Lexaria Bioscience Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	Apr. 09	CI
Lexaria Bioscience Corp. Receives New Patents in the Fields of Epilepsy and Anti-Viral Agents	Apr. 02	CI
Lexaria Bioscience Names Nelson Cabatuan as Finance Chief	Mar. 14	MT
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer	Mar. 14	CI
Sector Update: Health Care Stocks Retreating Late Afternoon	Mar. 05	MT
Sector Update: Health Care	Mar. 05	MT
Lexaria Bioscience to Start Diabetes, Weight Loss Animal Study; Shares Rise	Mar. 05	MT
Maxim Group Adjusts Lexaria Bioscience Price Target to $12 From $3, Maintains Buy Rating	Mar. 05	MT
Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1	Mar. 05	CI
Lexaria Bioscience Corp. Signs Contracts to Begin Animal Study Well-A24-1	Mar. 04	CI
Lexaria Bioscience Corp. Announces 7% Weight Loss in Animals Supports in its Next 8-Week Animal Study	Mar. 04	CI
Lexaria Bioscience Corp. Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial	Mar. 01	CI
Lexaria Bioscience Corp. Submits Investigational New Drug Application	Jan. 30	CI
Lexaria Bioscience Corp. Unveils Extensive Planned 2024 GLP-1 Study Program	Jan. 16	CI
Lexaria Bioscience Corp. Reports Earnings Results for the First Quarter Ended November 30, 2023	Jan. 12	CI
Lexaria Bioscience Corp. Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream	Jan. 11	CI
Lexaria Bioscience Corp. Improves Delivery, Efficacy of Glp-1 Agonists Through Proprietary Drug-Delivery Platform	Jan. 09	CI
Lexaria Bioscience Corp. Announces Positive Final Results from its Recently Completed Human Pilot Study #1 for the Oral Performance of the Rybelsus(R)-Branded GLP-1 Drug Semaglutide	Jan. 04	CI
Lexaria Bioscience Set to File Investigational New Drug Application for Hypertension Trial Within 45 Days	Dec. 07	MT
Lexaria Bioscience Corp. Announces Investigational New Drug Application Filing Update	Dec. 07	CI
Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study	Nov. 27	CI
Lexaria Bioscience Corp. Reports Earnings Results for the Full Year Ended August 31, 2023	Nov. 20	CI
Lexaria Bioscience Corp. Evaluates Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs	23-10-31	CI

Chart Lexaria Bioscience Corp.

Duration

Period

More charts

Company Profile

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Companyâs patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.

Sector

Pharmaceuticals

Calendar

2024-04-23 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Lexaria Bioscience Corp.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.25 USD

Average target price

11 USD

Spread / Average Target

+388.89%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LEXARIA BIOSCIENCE CORP.	+80.00%	28.99M
ELI LILLY AND COMPANY	+27.97%	672B
NOVO NORDISK A/S	+23.58%	550B
JOHNSON & JOHNSON	-7.02%	351B
MERCK & CO., INC.	+14.85%	317B
ABBVIE INC.	+6.25%	292B
ASTRAZENECA PLC	+2.96%	211B
NOVARTIS AG	-0.41%	203B
ROCHE HOLDING AG	-10.02%	194B
PFIZER, INC.	-11.81%	144B

Other Pharmaceuticals